The life sciences industry is at a turning point in corporate communications. Treating Investor Relations (IR) and External Communications (EC) as separate functions no longer meets the demands of today’s complex stakeholder landscape. Investors expect consistent narratives aligned with public positioning, media outlets seek compelling yet scientifically accurate stories, and regulators require compliance across all channels.
This white paper introduces a practical framework for integrating IR and EC into a unified approach. You’ll learn why integration is critical, the challenges companies face, and how to operationalize effective strategies that ensure message consistency, regulatory compliance, and stakeholder engagement.
What you'll learn:
- Why life sciences companies must unify Investor Relations (IR) and External Communications (EC) to meet investor, media, and regulatory expectations.
- How to operationalize integrated IREC through a phased roadmap, covering foundational audits, channel-specific messaging, execution strategies, and optimization strategies.
- Lessons from successful implementations, including IPO preparation, funding milestone communications, and product launches.
Discover how integrated communications can become your competitive advantage
Explore more resources
The Price Reckoning Series Part 3: The Global Repercussion
Lance Grady, EVP Managing Partner, Global HEOR & Access Strategy Richard Macauley, SVP, International Access Strategy...
Compelling Science: The Key to Effective Scientific Narratives
Jason McDonough | Senior Vice President, Medical Strategy, Medical Communications
The Do’s and Don’ts of Biotech Investor Relations and PR
Hannah Deresiewicz | EVP, Managing Director, Precision AQ Jessica Griffith | SVP, PR, Precision AQ